H.C. Wainwright is initiating coverage of atai Life Sciences with a Buy rating and $40/share price target. atai is aiming to bring meaningful change to mental health challenges through psychedelic derived medicines and digital therapeutics.
Get the Headlines & Market Updates
Be the first to see new company features, exclusive interviews and breaking news. Subscribe now.